SynthesisThe Indian journal of medical research2025
Cardiovascular safety of gabapentinoids gabapentin & pregabalin: A systematic review.
Synthesis in The Indian journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Migraine and risk of all-cause mortality and specific cause mortality: a systematic review and meta-analysis.The journal of headache and pain · 2025Pooled it
- Signals of Venous Thromboembolism Risk from Drug-Drug Interactions Involving Benzodiazepines and Other Sedative Hypnotics: Self-Controlled Case Series Analyses.Clinical drug investigation · 2026Article
- Pregabalin and atypical NSTEMI presentation in a diabetic woman (masked myocardial ischemia): A case report.Medicine internationalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & objectives A few propensity-score-matched cohort studies have suggested increased cardiovascular events with gabapentinoids (gabapentin/pregabalin). This systematic review analysed the cardiovascular safety of gabapentin and pregabalin in clinical practice. Methods Databases were searched for articles examining the occurrence of cardiovascular events with gabapentin and pregabalin in different clinical conditions. The primary outcome was to look at the occurrence of myocardial infarction (MI) and stroke. Secondary outcomes were to look at the occurrence of deep venous thrombosis (DVT), peripheral artery disease (PAD), pulmonary thrombo-embolism (PTE), heart failure (HF) and atrial fibrillation (AF). Results Data from five cohort studies (10,85,488 patients) were analysed. Gabapentin use was associated with increased risk of MI after one year of [Hazard ratio (HR) 1.31(1.14,1.52); I2=0%; P=0.0002] use. Gabapentinoids were associated with increased risk of stroke after five years of use [HR 1.44 (1.04, 2.01); I2=86%; P=0.03]. Heart failure was not increased with the use of gabapentinoids. Their chronic use was associated with increased risk of PVD after one year [HR 1.41(1.18, 1.67); P=0.0001] and five years [HR 1.58 (1.16, 2.15); I2=83%; P=0.003] use. Gabapentinoid use was associated with increased risk of DVT after three months [HR 1.37(1.21, 1.55); P<0.00001], one-year [HR 1.42 (1.15, 1.74); P=0.0009], and five years [HR 1.78 (1.31,2.40); I2=71%; P=0.0002] use. Their use was associated with increased risk of pulmonary embolism after three months [HR 1.27 (1.09, 1.46); P=0.002], one-year [HR 1.23 (1.01, 1.40); P=0.04], and five years of [HR 1.86 (1.64, 2.09); I2=0%; P<0.0001] use. Interpretation & conclusions The use of gabapentinoids was associated with increased risks of thrombotic events as early as three months of use, and with increased risk of cardiovascular events on prolonged use of more than a year duration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.